spacer
home > pmps > summer 2009 > within the limits
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Within the Limits

When it comes to the distribution of pharmaceutical and biotech products within Europe, few would disagree that the landscape has changed significantly. Direct-to-pharmacy developments in the UK and other countries, along with new products with differing and more challenging transportation characteristics, have promoted the need for the logistics industry to evolve and provide a more diversified range of services.

Inevitably, as the supply chain becomes more integrated with the end user, it becomes more complex to manage, largely as a result of more frequent but smaller shipments. From a regulatory compliance viewpoint, this can be a real challenge, not least in terms of temperature stability, particularly since in the next two to three years over 50 per cent of all newly approved medicines will be biopharmaceuticals which have particular temperature sensitivities during transportation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jason Breakwell has a BSc in Transport & Logistics Management from Aston University in the UK. During a 10-year career at Netherlands-based Rutges Cargo, he has been instrumental in its development as a truck operator serving customers in the air cargo, hi-tech, pharmaceutical and perishable sectors. As Commercial Manager, he is involved in all aspects of the business, from operations and account management to product development and sales. He is also a Board Member of the Transported Asset Protection Association (TAPA) in the Europe, Middle East and Africa region and, as Strategic Lead of the group, is helping to steer the public/private sector partnership in its campaign to fight cargo crime.
spacer
Jason Breakwell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Offers First Patient-Administered ECG Assessment for Continuation of Clinical Trials during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a first-of-its-kind partnership with AliveCor, the leader in AI-based, personal ECG technology. The partnership enables ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement